Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for two distinct indications: type 2 diabetes management (Ozempic, 2017) and chronic weight management (Wegovy, 2021). It is the most clinically validated peptide currently in widespread use — backed by multiple large-scale randomized controlled trials and a decade of regulatory-grade safety data.
Unlike most peptides discussed in research communities, semaglutide occupies a unique position: it is simultaneously a pharmaceutical drug with extensive human trial data and a compound that is misused outside of prescribed contexts, obtained through compounding pharmacies and online grey-market vendors.
This guide focuses on the science. The distinction between approved use and off-label/compounded use is addressed in the regulatory section.
The GLP-1 System
To understand semaglutide, you need to understand GLP-1 itself.
Glucagon-like peptide-1 is an incretin hormone produced in the L-cells of the intestinal epithelium in response to food. It does several things:
- Stimulates insulin secretion from pancreatic beta cells — in a glucose-dependent manner, meaning it only triggers insulin when blood glucose is elevated (reducing hypoglycemia risk)
- Suppresses glucagon release from alpha cells, reducing hepatic glucose output
- Slows gastric emptying, reducing the rate at which glucose from food enters circulation
- Activates satiety centers in the hypothalamus, reducing appetite and food intake
- Has cardioprotective effects via GLP-1 receptors in cardiac tissue and vasculature
The endogenous half-life of GLP-1 is 1–2 minutes — rapidly degraded by dipeptidyl peptidase-4 (DPP-4). Semaglutide was engineered to circumvent this: its C18 fatty acid chain binds albumin, dramatically extending its half-life to approximately 7 days in humans, enabling once-weekly dosing.
Structural Engineering
Native GLP-1 cannot be a useful drug because it is degraded within minutes. Semaglutide’s design solved three problems:
- DPP-4 resistance: A single amino acid substitution (alanine → alpha-aminoisobutyric acid at position 8) prevents DPP-4 cleavage
- Extended half-life: A C18 fatty diacid chain attached to lysine 26 via a hydrophilic linker enables non-covalent albumin binding, extending t½ to ~165 hours
- Subcutaneous bioavailability: ~89% bioavailability after subcutaneous injection, enabling once-weekly dosing
An oral formulation (Rybelsus) uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to enable gastrointestinal uptake — though bioavailability is only ~1% and requires specific administration conditions (fasting, 30 minutes before food).
Key Clinical Trials
Semaglutide has an unusually robust clinical evidence base. Here are the landmark trials:
SUSTAIN Program (Type 2 Diabetes)
The SUSTAIN trials (1–10) established semaglutide’s efficacy for glycemic control. Key findings from SUSTAIN-6, the cardiovascular outcomes trial:
- Participants: 3,297 adults with T2D at high cardiovascular risk
- Duration: 2 years
- Outcome: 26% relative risk reduction in MACE (major adverse cardiovascular events — cardiovascular death, non-fatal MI, non-fatal stroke)
- HbA1c reduction: ~1.5% from baseline (subcutaneous 1.0mg/week)
- Weight loss: ~4–6 kg at 2 years
STEP Program (Obesity/Weight Management)
The STEP trials (1–5) established the weight loss profile that made semaglutide culturally prominent:
STEP 1 (2021, NEJM): The defining trial
- Participants: 1,961 adults without diabetes, BMI ≥30 (or ≥27 with weight-related comorbidity)
- Dose: 2.4mg subcutaneous weekly (higher than diabetes dose)
- Duration: 68 weeks
- Weight loss: 14.9% of body weight vs 2.4% placebo
- Clinically meaningful ≥5% weight loss: 86.4% of treatment group vs 31.5% placebo
STEP 4: Demonstrated that weight regain occurs rapidly upon discontinuation — the mean regain was 6.9% at 48 weeks after stopping, partially reversing the 17.4% loss during active treatment. This established semaglutide as a long-term or chronic therapy rather than a finite course.
SELECT Trial (2023, NEJM)
Perhaps the most significant recent trial: SELECT enrolled 17,604 overweight/obese adults without diabetes.
- Primary endpoint: Non-fatal MI, non-fatal stroke, or cardiovascular death
- Result: 20% relative risk reduction in MACE
- Implication: Cardiovascular benefit in obesity appears to extend beyond the diabetic population — and is only partially explained by weight loss itself
This trial is reshaping how cardiologists think about GLP-1 agonists.
Mechanisms Beyond Glucose Control
The scale of weight loss and cardiovascular benefit from semaglutide has driven intense research into mechanisms beyond simple appetite suppression.
Hypothalamic Action
GLP-1 receptors in the arcuate nucleus and other hypothalamic regions modulate hunger and reward signaling. Imaging studies show reduced activation of brain regions involved in food reward (including the nucleus accumbens) with GLP-1 agonist treatment — suggesting effects on hedonic eating, not just homeostatic hunger.
This partly explains anecdotal reports of reduced “food noise” and decreased craving for alcohol and other addictive substances. Small trials are now underway examining semaglutide for alcohol use disorder.
Direct Cardiac Effects
The cardiovascular benefit in SELECT cannot be entirely explained by weight loss or glucose reduction. Research points to:
- Direct anti-inflammatory effects in coronary arteries
- Reduced oxidative stress in cardiac tissue
- Attenuation of foam cell formation in atherosclerotic plaques
- Possible effects on cardiac fibrosis
Potential Neuroprotective Properties
Epidemiological data from large claims databases show lower incidence of Alzheimer’s and Parkinson’s diagnoses in people on GLP-1 agonists. Several trials are underway (the EVOKE trial and others) to prospectively test whether this is causal.
GLP-1 receptors are expressed in the substantia nigra and hippocampus; GLP-1 agonists reduce neuroinflammation and alpha-synuclein aggregation in preclinical models.
Side Effect Profile
Semaglutide’s adverse effect profile is well-documented from large-scale trial data:
Common (>10%)
- Nausea: ~44% of participants, typically worse during dose escalation. Usually resolves within weeks
- Vomiting: ~24%, co-occurring with nausea
- Diarrhea: ~29%
- Constipation: ~24%
Most GI side effects are managed by slow dose escalation (starting at 0.25mg weekly for 4 weeks before increasing).
Serious but Rare
- Pancreatitis: Incidence not significantly elevated vs placebo in SUSTAIN/STEP data, but mechanistic concern persists; contraindicated with personal/family history
- Gastroparesis: Case reports of severe delayed gastric emptying, particularly at higher doses; relevant for surgical anesthesia planning
- Thyroid C-cell tumors: Observed in rodents at supratherapeutic doses; not observed in human trial data; contraindicated with personal/family history of medullary thyroid carcinoma or MEN-2
- Gallbladder disease: Cholecystitis and cholelithiasis rates are elevated; likely related to rapid weight loss
Muscle Mass
Rapid weight loss with semaglutide includes a significant lean mass component — estimates range from 25–40% of total weight lost being fat-free mass. This has led to concerns about sarcopenia, particularly in older adults. Resistance training and adequate protein intake are strongly recommended for anyone on weight-loss doses.
Regulatory Status
Semaglutide is a fully regulated pharmaceutical with different legal status depending on form and indication:
Approved and legal (with prescription):
- Ozempic (0.5mg, 1mg, 2mg SC weekly) — Type 2 diabetes
- Wegovy (2.4mg SC weekly) — Chronic weight management (BMI ≥30, or ≥27 with comorbidity)
- Rybelsus (oral, 7mg/14mg daily) — Type 2 diabetes
Compounded semaglutide: During the FDA shortage period (2022–2024), compounding pharmacies legally produced semaglutide. The FDA has indicated it intends to restrict this once shortage designations are lifted. Compounded versions vary significantly in quality, purity, and dosing accuracy — acetate salt vs sodium salt vs base compound formulations are not interchangeable and have different potencies.
Grey market / research chemical: Semaglutide is not scheduled as a controlled substance, but self-administration without a prescription carries the full risks of unvalidated sources, including misdosing, contamination, and lack of pharmaceutical-grade purity.
Emerging Indications Under Investigation
The breadth of GLP-1 receptor expression is driving exploration far beyond metabolic disease:
- NASH/MASH: Non-alcoholic steatohepatitis; Phase 3 trials showing promising results
- Heart failure: STEP-HFpEF trial showed significant improvement in heart failure with preserved ejection fraction
- Obstructive sleep apnea: SURMOUNT-OSA trial demonstrated significant AHI reduction
- Chronic kidney disease: Phase 3 data showing nephroprotective effects
- Alcohol and substance use disorder: Multiple trials recruiting
Summary Table
| Parameter | Value |
|---|---|
| Mechanism | GLP-1 receptor agonist |
| Half-life | ~7 days (subcutaneous) |
| Bioavailability (SC) | ~89% |
| Weight loss (2.4mg) | ~15% body weight at 68 weeks |
| HbA1c reduction | ~1.5–2.0% |
| CV risk reduction (SELECT) | 20% MACE |
| Major adverse effects | GI (nausea, vomiting, diarrhea) |
| Contraindications | MEN-2, medullary thyroid carcinoma history |
Bottom Line
Semaglutide is the most clinically validated peptide in modern medicine. The trial evidence for weight loss and cardiovascular risk reduction is Category A by any standard — large-scale, well-powered, placebo-controlled, with hard cardiovascular outcomes. The biology is well understood, the side effect profile is well-characterized, and the regulatory apparatus ensures quality control in approved pharmaceutical forms.
The grey market and compounding situations introduce real risks — misdosing, purity questions, and the absence of medical supervision for a compound that does require appropriate clinical context.
Semaglutide is a prescription-only medication. This guide is for educational purposes only. Consult a licensed physician to determine if it is appropriate for your situation.
Found this useful? Share it with someone who'd benefit.